S Stevens Negus Selected Research

Cocaine-Related Disorders (Cocaine Addiction)

1/2018	Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.
1/2018	Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.
4/2017	Repeated 7-Day Treatment with the 5-HT2C Agonist Lorcaserin or the 5-HT2A Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys.
1/2017	Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.
12/2016	Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.
8/2016	Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys.
4/2016	Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.
10/2015	Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys.
6/2015	Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.
1/2015	Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Stevens Negus Research Topics

Disease

38	Pain (Aches) 02/2022 - 03/2004
24	Cocaine-Related Disorders (Cocaine Addiction) 01/2018 - 05/2003
15	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 05/2003
9	Substance-Related Disorders (Drug Abuse) 06/2022 - 05/2003
6	Acute Pain 01/2022 - 11/2012
6	Hyperalgesia 01/2016 - 05/2006
4	Hypersensitivity (Allergy) 01/2020 - 03/2004
4	Tobacco Use Disorder (Nicotine Dependence) 10/2015 - 05/2003
3	Inflammation (Inflammations) 01/2021 - 01/2012
3	Neuralgia (Stump Neuralgia) 01/2020 - 01/2016
2	Neoplasms (Cancer) 01/2022 - 01/2018
2	Chronic Pain 07/2021 - 01/2021
2	Body Weight (Weight, Body) 01/2018 - 12/2013
2	Amphetamine-Related Disorders (Addiction, Amphetamine) 01/2018 - 09/2004
1	Hallucinations (Hallucination) 06/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Colitis 01/2021
1	Crohn Disease (Crohn's Disease) 01/2021
1	Brain Hypoxia (Cerebral Hypoxia) 12/2020
1	Necrosis 01/2020
1	Pruritus (Itching) 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018

Drug/Important Bio-Agent (IBA)

29	Opioid Analgesics (Opioids)IBA 02/2022 - 09/2004
23	Analgesics (Analgesic Drugs)IBA 02/2022 - 06/2006
21	Pharmaceutical PreparationsIBA 01/2022 - 05/2003
17	Morphine (MS Contin)FDA LinkGeneric 01/2021 - 06/2006
14	Cocaine (Cocaine HCl)IBA 01/2018 - 05/2003
6	Ketoprofen (Orudis)FDA LinkGeneric 01/2021 - 03/2012
6	Methadone (Dolophine)FDA LinkGeneric 12/2020 - 05/2003
6	AcidsIBA 01/2018 - 08/2009
6	Opioid Receptors (Opioid Receptor)IBA 06/2015 - 11/2003
5	Serotonin (5 Hydroxytryptamine)IBA 01/2018 - 03/2013
5	Amphetamine (Amfetamine)FDA LinkGeneric 01/2018 - 09/2004
5	Dopamine (Intropin)FDA LinkGeneric 01/2017 - 03/2013
5	Nicotine FDA Link 11/2015 - 05/2003
5	Dextroamphetamine (Dexedrine)FDA LinkGeneric 06/2015 - 05/2003
4	Fentanyl (Sublimaze)FDA LinkGeneric 01/2022 - 02/2015
4	Freund's AdjuvantIBA 07/2021 - 09/2014
4	mu Opioid Receptors (mu Opioid Receptor)IBA 03/2021 - 08/2009
4	4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamideIBA 04/2012 - 10/2006
4	Capsaicin (Zostrix)FDA Link 01/2012 - 09/2008
3	Naltrexone (ReVia)FDA LinkGeneric 01/2022 - 01/2018
3	Heroin (Diamorphine)IBA 01/2022 - 01/2018
3	GTP-Binding Proteins (G-Protein)IBA 01/2021 - 01/2018
3	Buprenorphine (Subutex)FDA LinkGeneric 12/2020 - 02/2015
3	Formaldehyde (Formol)FDA Link 01/2020 - 09/2014
3	Biological ProductsIBA 01/2019 - 03/2004
3	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2018 - 12/2007
3	Nalbuphine (Nubain)FDA LinkGeneric 02/2015 - 11/2010
2	Lactic Acid (Lactate)FDA LinkGeneric 07/2021 - 07/2009
2	((3- methoxythiophen- 2- yl)methyl)((2- (9- (pyridin- 2- yl)- 6- oxaspiro(4.5)decan- 9- yl)ethyl))amineIBA 01/2021 - 12/2020
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021 - 03/2012
2	VaccinesIBA 01/2021 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 01/2018
2	Dopamine Agonists (Dopamine Agonist)IBA 01/2018 - 01/2017
2	LigandsIBA 01/2017 - 11/2003
2	phendimetrazine (Bontril)FDA LinkGeneric 12/2016 - 04/2016
2	Appetite Depressants (Anorectics)IBA 12/2016 - 04/2016
2	Dronabinol (THC)FDA LinkGeneric 01/2016 - 11/2012
2	N-Methylaspartate (NMDA)IBA 12/2014 - 07/2014
2	Ketamine FDA LinkGeneric 12/2014 - 07/2014
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 06/2013 - 03/2013
2	delta Opioid Receptors (delta Opioid Receptor)IBA 04/2012 - 01/2012
2	rebemideIBA 01/2012 - 10/2006
2	Haloperidol (Haldol)FDA LinkGeneric 08/2009 - 06/2006
2	Acetic Acid (Vinegar)FDA LinkGeneric 08/2009 - 06/2006
1	phenethylamineIBA 06/2022
1	volinanserinIBA 06/2022
1	ErgolinesIBA 06/2022
1	Hallucinogens (Psychedelics)IBA 06/2022
1	tryptamineIBA 06/2022
1	4-iodo-2,5-dimethoxyphenylisopropylamine (DOI-P)IBA 06/2022
1	Lysergic Acid Diethylamide (LSD)IBA 06/2022
1	NociceptinIBA 01/2022
1	Opioid Peptides (Opioid Peptide)IBA 01/2022
1	Ro 64-6198IBA 01/2022
1	Biological FactorsIBA 01/2021
1	Sulfonic AcidsIBA 01/2021
1	Oxycodone (Oxycontin)FDA LinkGeneric 12/2020
1	KetorolacIBA 01/2019
1	KRM-II-81IBA 01/2019
1	Diazepam (Valium)FDA LinkGeneric 01/2019
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2018
1	AntipruriticsIBA 01/2018
1	ArrestinIBA 01/2018
1	TRK 820IBA 01/2018
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2017
1	N- (4- (4- (2,3- dichlorophenyl)piperazin- 1- yl)but- 2- enyl)- 4- pyridine- 2- ylbenzamideIBA 01/2017
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2017
1	Bupropion (Wellbutrin)FDA LinkGeneric 01/2016
1	HydrogenIBA 11/2015
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 11/2015
1	tartaric acid (tartrate)FDA Link 11/2015

Therapy/Procedure

10	Self Administration (Administration, Self) 01/2022 - 12/2004
9	Drug Therapy (Chemotherapy) 01/2019 - 05/2003
7	Analgesia 01/2018 - 06/2006
2	Injections 07/2021 - 07/2009
2	Intraperitoneal Injections 06/2015 - 04/2012
1	Secondary Prevention 12/2020